According to a recent LinkedIn post from Cagent Vascular Inc, the company is highlighting clinical education around its Serranator device and Serration Remodeling Therapy for peripheral arterial disease. The post references a discussion in which physicians review a first case using Serranator and indicates that additional educational content on how the therapy works across various lesion morphologies will follow.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The emphasis on clinician-to-clinician case review suggests an effort to drive awareness and adoption of Serranator among interventional specialists in the endovascular space. For investors, this focus on educational outreach could be seen as supporting procedure volume growth, strengthening physician engagement, and potentially enhancing the company’s competitive position in the PAD treatment market if it translates into broader clinical use over time.